Clarus Wealth Advisors acquired a new position in shares of Alkermes Plc (NASDAQ:ALKS) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 4,700 shares of the company’s stock, valued at approximately $257,000.

A number of other institutional investors have also recently modified their holdings of the business. Thornburg Investment Management Inc. grew its stake in shares of Alkermes by 39.8% during the third quarter. Thornburg Investment Management Inc. now owns 2,779,364 shares of the company’s stock valued at $141,303,000 after purchasing an additional 790,692 shares during the last quarter. Janus Henderson Group PLC grew its stake in shares of Alkermes by 13.7% during the third quarter. Janus Henderson Group PLC now owns 2,650,006 shares of the company’s stock valued at $134,726,000 after purchasing an additional 319,014 shares during the last quarter. Legal & General Group Plc grew its stake in shares of Alkermes by 2.0% during the third quarter. Legal & General Group Plc now owns 668,021 shares of the company’s stock valued at $33,962,000 after purchasing an additional 13,277 shares during the last quarter. Swiss National Bank grew its stake in shares of Alkermes by 1.3% during the third quarter. Swiss National Bank now owns 563,800 shares of the company’s stock valued at $28,664,000 after purchasing an additional 7,400 shares during the last quarter. Finally, Ameriprise Financial Inc. grew its stake in shares of Alkermes by 8.8% during the third quarter. Ameriprise Financial Inc. now owns 543,486 shares of the company’s stock valued at $27,631,000 after purchasing an additional 44,173 shares during the last quarter. 99.31% of the stock is currently owned by hedge funds and other institutional investors.

Alkermes Plc (NASDAQ ALKS) opened at $56.00 on Thursday. Alkermes Plc has a 52 week low of $46.42 and a 52 week high of $64.04. The company has a quick ratio of 2.72, a current ratio of 3.05 and a debt-to-equity ratio of 0.23.

Several analysts have recently commented on ALKS shares. Barclays cut shares of Alkermes from an “overweight” rating to an “equal weight” rating and decreased their price target for the company from $66.00 to $50.00 in a research note on Monday, October 16th. Mizuho set a $81.00 price objective on shares of Alkermes and gave the company a “buy” rating in a research note on Saturday, October 21st. ValuEngine cut shares of Alkermes from a “hold” rating to a “sell” rating in a research note on Monday, October 23rd. Citigroup set a $62.00 price objective on shares of Alkermes and gave the company a “hold” rating in a research note on Thursday, October 26th. Finally, Credit Suisse Group reduced their price objective on shares of Alkermes from $70.00 to $66.00 and set an “outperform” rating on the stock in a research note on Friday, October 27th. Eight equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The stock has an average rating of “Hold” and an average price target of $64.17.

In other Alkermes news, CAO Iain Michael Brown sold 10,652 shares of the stock in a transaction on Saturday, December 29th. The shares were sold at an average price of $54.81, for a total value of $583,836.12. Following the sale, the chief accounting officer now directly owns 16,943 shares in the company, valued at $928,645.83. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Shane Cooke sold 72,793 shares of the stock in a transaction on Friday, February 2nd. The stock was sold at an average price of $60.55, for a total transaction of $4,407,616.15. Following the completion of the sale, the insider now owns 147,501 shares in the company, valued at $8,931,185.55. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 135,485 shares of company stock worth $8,227,502. Insiders own 5.34% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Clarus Wealth Advisors Acquires New Position in Alkermes Plc (ALKS)” was posted by Daily Political and is the sole property of of Daily Political. If you are accessing this story on another website, it was stolen and republished in violation of United States & international copyright & trademark legislation. The correct version of this story can be accessed at https://www.dailypolitical.com/2018/02/08/clarus-wealth-advisors-acquires-new-position-in-alkermes-plc-alks.html.

About Alkermes

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).

Want to see what other hedge funds are holding ALKS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alkermes Plc (NASDAQ:ALKS).

Institutional Ownership by Quarter for Alkermes (NASDAQ:ALKS)

Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter.